The same drug combination is being further evaluated in the TROPION-Lung10 phase III study, which targets patients with non-squamous a/mNSCLC who are PD-L1 high expressors (tumor cell expression ≥ 50%) and do not have AGAs. This evidence concerns the gene CD274 and neoplasm.